Close Menu

NEW YORK – Credo Diagnostics Biomedical announced Friday its combination VitaPCR Influenza A&B/SARS-CoV-2 test received CE-IVD marking. 

The point-of-care RT-PCR test delivers results from one nasopharyngeal sample in 20 minutes and can be used on the firm's VitaPCR instrument. The platform can perform 24 runs per day with one sample per run and doesn't need "highly trained personnel," Credo said in a presentation on the test.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

European regulators have begun a rolling review of Russia's Sputnik V SARS-CoV-2 vaccine, Reuters reports.

Science reports that Science Foundation Ireland is seeking annual budget increases.

According to the Financial Times, a UK university group is pushing Elsevier to lower its journal fees.

In Nature this week: satellite tracking and genome sequencing combination used to examine migration patterns of peregrine falcons, and more.